ezetimibe has been researched along with Disease Models, Animal in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (32.65) | 29.6817 |
| 2010's | 26 (53.06) | 24.3611 |
| 2020's | 7 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Aytan, H; Bayrak, G; Tapdıgova, R; Yılmaz, BC | 1 |
| Chung, KS; Gee, HY; Kim, DY; Park, JY | 1 |
| Cao, Z; Chen, X; Liu, G; Liu, J; Wang, B; Wang, J; Wang, Y; Wu, Y; Xian, X; Xu, MJ; Yang, C; Zhang, F | 1 |
| Chen, SP; Li, X; Matei, N; Mo, J; Pang, JW; Tang, JP; Wang, WN; Yan, M; Yu, J; Zhang, JH | 1 |
| Chen, CC; Chen, HJ; Chen, JS; Liang, CL; Liu, KY; Wang, HK; Wang, KW; Yeh, LR | 1 |
| Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA | 1 |
| Cao, JT; Chen, K; Fan, YQ; Gao, L; Wang, CQ; Wang, Y; Xie, YS; Xu, ZJ; Yin, ZF; Zhang, HL | 1 |
| Antoku, Y; Egashira, K; Honda, K; Ichi, I; Koga, JI; Matoba, T; Nakano, K; Tsutsui, H | 1 |
| Komine, T; Mu, S; Suzuki, H; Takada, T; Tanaka, Y; Yamamoto, H; Yamanashi, Y | 1 |
| Jones, RD; Lopez, AM; Ramirez, CM; Repa, JJ; Taylor, AM; Turley, SD | 1 |
| Arya, N; Coutinho, EC; Dwivedi, J; Jain, KS; Khedkar, VM | 1 |
| Chuang, JC; Lopez, AM; Posey, KS; Turley, SD | 1 |
| Bandyopadhyay, S; Katare, OP; Singh, B | 1 |
| Balakrishnan, A; Cassis, LA; Daugherty, A; Howatt, DA; Liu, J; Lu, H; Moorleghen, JJ; Sorci-Thomas, M | 1 |
| Chang, E; Kim, L; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ | 1 |
| Andrade-Neto, VV; Atella, GC; Canto-Cavalheiro, MM; Costa, PR; Cunha-Júnior, EF; Fernandes, TA; Torres-Santos, EC | 1 |
| Ahn, SC; Jang, HJ; Jeon, TI; Kim, KY; Osborne, TF; Park, KI; Seo, J; Seo, YK; Shin, IW; Suh, PG; Yang, YR | 1 |
| Gao, X; Jacobs, RL; Kassiri, Z; Lingrell, S; Takawale, A; van der Veen, JN; Vance, DE | 1 |
| Dixit, RP; Nagarsenker, MS | 1 |
| Floreani, A | 1 |
| Amigo, L; Arrese, M; Azocar, L; Jarufe, N; Lammert, F; Miquel, JF; Molina, H; Nervi, F; Pimentel, F; Zúñiga, S | 1 |
| Aragoncillo, P; Fernández-Cruz, A; Gómez-Garre, D; González-Rubio, ML; Granados, R; Muñoz-Pacheco, P | 1 |
| Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O | 1 |
| Almazan, F; Choi, SH; Crosier, P; Fang, L; Hall, C; Hansen, LF; Hartvigsen, K; Juliano, J; Klemke, RL; Miller, ER; Miller, YI; Pattison, J; Stoletov, K; Witztum, JL | 1 |
| Fujita, K; Inamori, M; Kirikoshi, H; Kubota, K; Masaki, N; Mizoue, T; Nagashima, Y; Nakajima, A; Nozaki, Y; Saito, S; Shinohara, Y; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M | 1 |
| Atrott, K; Bourayou, R; Dietrich, T; Fleck, E; Graf, K; Gräfe, M; Hucko, T; Jahnke, C; Klein, C; Paetsch, I; Schnackenburg, B; Stawowy, P | 1 |
| Tomkin, GH | 1 |
| Elisaf, M; Kalogirou, M; Tsimihodimos, V | 1 |
| Ahn, Y; Baek, JY; Cho, JG; Cho, JS; Her, SH; Hong, YJ; Jeong, MH; Jin, SW; Kang, JC; Kim, HD; Kim, JH; Lim, KS; Park, JC; Sim, DS; Yoon, HJ | 1 |
| Mangat, R; Proctor, SD; Russell, JC; Uwiera, R; Vine, DF; Wang, Y; Warnakula, S | 1 |
| Fujii, H; Kawada, N; Ogawa, T; Yoshizato, K | 1 |
| Inagaki, M; Ishigami, M; Kawase, R; Komuro, I; Masuda, D; Matsuyama, A; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tochino, Y; Tsubakio-Yamamoto, K; Yamashita, S; Yuasa-Kawase, M | 1 |
| Di Vizio, D; Freeman, MR; Insabato, L; Pelton, K; Schaffner, CP; Solomon, KR | 1 |
| Beigneux, AP; Bensadoun, A; Davies, BS; Fong, LG; Gin, P; Reue, K; Tontonoz, P; Tu, Y; Voss, C; Walzem, RL; Weinstein, MM; Young, SG | 1 |
| Colquhoun, D; Hamilton-Craig, I; Kostner, K; Woodhouse, S | 1 |
| Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS | 1 |
| Davis, HR; Lowe, RS; Neff, DR | 1 |
| Adeli, K; Baker, C; Hussain, MM; Iqbal, J; Lino, M; Naples, M | 1 |
| Beuers, U; Bosma, PJ; de Knegt, RJ; de Waart, DR; Duijst, S; Finel, M; Montenegro-Miranda, PS; Sneitz, N; Ten Bloemendaal, L | 1 |
| Fujisawa, K; Kuwashiro, S; Matsumoto, T; Nishina, H; Oishi, T; Sakaida, I; Terai, S | 1 |
| Itoh, T; Komori, K; Maekawa, T; Morisaki, K | 1 |
| Deushi, M; Haraguchi, M; Ishii, H; Ito, M; Kawakami, A; Nomura, M; Okazaki, M; Yoshida, M | 1 |
| Acton, S; Braun, A; Broschat, KO; Krieger, M; Krul, ES; Napawan, N; Stagliano, N; Yesilaltay, A | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Cook, J; Davis, H; Hoos, L; Hwa, JJ; Tetzloff, G; van Heek, M; Zheng, S | 1 |
| Angelin, B; Bonde, Y; Gälman, C; Matasconi, M; Rudling, M | 1 |
| Mendez-Sanchez, N; Portincasa, P; Uribe, M; Wang, DQ; Wang, HH | 1 |
| Rudel, LL | 1 |
5 review(s) available for ezetimibe and Disease Models, Animal
| Article | Year |
|---|---|
Pleiotropic effects of ezetimibe: do they really exist?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Disease Models, Animal; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Inflammation Mediators; Lipid Metabolism; Platelet Aggregation; Treatment Outcome | 2010 |
Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biological Transport; Cholesterol; Chylomicrons; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Intestinal Absorption; Intestinal Mucosa; Intestines; Metabolic Syndrome; Rats | 2010 |
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Effects of ezetimibe on atherosclerosis in preclinical models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Disease Models, Animal; Drug Evaluation, Preclinical; Ezetimibe; Mice; Mice, Knockout; Rabbits; Risk; Simvastatin | 2011 |
Preclinical and clinical pharmacology of a new class of lipid management agents.
Topics: Absorption; Animals; Anticholesteremic Agents; Arteriosclerosis; Azetidines; Cholesterol, LDL; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Ezetimibe; Mice; Rats | 2002 |
1 trial(s) available for ezetimibe and Disease Models, Animal
| Article | Year |
|---|---|
Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones.
Topics: Adult; Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Bile; Cholelithiasis; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Ezetimibe; Female; Gallbladder Emptying; Gallstones; Humans; Intestinal Absorption; Lipoproteins; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Middle Aged; RNA, Messenger; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Time Factors | 2008 |
43 other study(ies) available for ezetimibe and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Antilipidemic ezetimibe induces regression of endometriotic explants in a rat model of endometriosis with its anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Endometriosis; Ezetimibe; Female; Humans; Rats; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2022 |
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models.
Topics: Adult; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Glucose; Humans; Liver; Mice; Non-alcoholic Fatty Liver Disease | 2023 |
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cholesterol, LDL; Cricetinae; Diet, High-Fat; Disease Models, Animal; Ezetimibe; Heterozygote; Humans; Hyperlipidemias; Male; PCSK9 Inhibitors; Receptors, LDL; Treatment Outcome; Triglycerides | 2019 |
Ezetimibe Attenuates Oxidative Stress and Neuroinflammation via the AMPK/Nrf2/TXNIP Pathway after MCAO in Rats.
Topics: AMP-Activated Protein Kinases; Animals; Cell Cycle Proteins; Disease Models, Animal; Ezetimibe; Infarction, Middle Cerebral Artery; Inflammation; Male; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2020 |
Simvastatin-Ezetimibe enhances growth factor expression and attenuates neuron loss in the hippocampus in a model of intracerebral hemorrhage.
Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Hippocampus; Intercellular Signaling Peptides and Proteins; Male; Maze Learning; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Simvastatin | 2021 |
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic Disease; Diet; Disease Models, Animal; Disease Progression; Ezetimibe; Fatty Liver; Feeding Behavior; Gallbladder Neoplasms; Gallstones; Inflammation; Male; Metaplasia; Mice, Inbred C57BL; Precancerous Conditions; Spleen | 2020 |
Model design for screening effective Antihyperlipidemic drugs using zebrafish system.
Topics: Animals; Atorvastatin; Biomarkers; Cholesterol; Diet, High-Fat; Disease Models, Animal; Drug Discovery; Ezetimibe; Fenofibrate; High-Throughput Screening Assays; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Male; Triglycerides; Zebrafish | 2017 |
Lipid-Lowering Therapy With Ezetimibe Decreases Spontaneous Atherothrombotic Occlusions in a Rabbit Model of Plaque Erosion: A Role of Serum Oxysterols.
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Arterial Occlusive Diseases; Atherosclerosis; Biomarkers; Cells, Cultured; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oxysterols; Plaque, Atherosclerotic; Rabbits; Rats; Rosuvastatin Calcium; Signal Transduction; Thrombosis; Vascular System Injuries | 2018 |
Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet-Induced Atherosclerosis in LDL Receptor Mutant Mice.
Topics: Animals; Atherosclerosis; Cholesterol; Diet, Western; Disease Models, Animal; Ezetimibe; Hyperlipidemias; Intestinal Mucosa; Liver; Male; Membrane Transport Proteins; Mice; Mutation; Receptors, LDL; Up-Regulation | 2019 |
Ontogenesis and Modulation of Intestinal Unesterified Cholesterol Sequestration in a Mouse Model of Niemann-Pick C1 Disease.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Cholesterol; Disease Models, Animal; Ezetimibe; Female; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Intracellular Signaling Peptides and Proteins; Male; Mice, 129 Strain; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2 | 2020 |
Design, synthesis and biological evaluation of some 2-azetidinone derivatives as potential antihyperlipidemic agents.
Topics: Animals; Azetidines; Binding Sites; Biomarkers; Crystallography, X-Ray; Disease Models, Animal; Drug Design; Ezetimibe; Female; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Membrane Proteins; Membrane Transport Proteins; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Polyethylene Glycols; Protein Conformation; Rats; Rats, Wistar | 2013 |
Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.
Topics: Animals; Azetidines; Body Weight; Cholesterol; Cholesterol Ester Storage Disease; Disease Models, Animal; Ezetimibe; Hepatomegaly; Intestinal Mucosa; Intestines; Liver; Liver Function Tests; Male; Mice; Organ Size; Rats; Sterol Esterase; Triglycerides | 2014 |
Development of optimized supersaturable self-nanoemulsifying systems of ezetimibe: effect of polymers and efflux transporters.
Topics: Animals; Anticholesteremic Agents; Azetidines; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Cholesterol, LDL; Disease Models, Animal; Drug Delivery Systems; Drug Stability; Emulsions; Ezetimibe; Female; Hypercholesterolemia; Intestinal Absorption; Intestine, Small; Lipids; Nanoparticles; Polymers; Rats; Rats, Sprague-Dawley; X-Ray Diffraction | 2014 |
Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice.
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Apolipoproteins E; Azetidines; Diet, Western; Disease Models, Animal; Ezetimibe; Female; Hypercholesterolemia; Male; Mice, Inbred C57BL; Mice, Knockout; Receptors, LDL; Sex Factors | 2015 |
Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
Topics: Animals; Anticholesteremic Agents; Autophagy; Biomarkers; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Fatty Liver; Gene Expression Regulation; Hepatocytes; Lipids; Liver; Macrolides; Male; Obesity; Palmitic Acid; Rats, Inbred OLETF; RNA, Messenger | 2015 |
Antileishmanial Activity of Ezetimibe: Inhibition of Sterol Biosynthesis, In Vitro Synergy with Azoles, and Efficacy in Experimental Cutaneous Leishmaniasis.
Topics: Animals; Azoles; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Ezetimibe; Inhibitory Concentration 50; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Mice, Inbred BALB C; Sterols; Trypanocidal Agents | 2016 |
SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy.
Topics: Animals; Anticholesteremic Agents; Autophagosomes; Autophagy; Cells, Cultured; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Group VI Phospholipases A2; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Signal Transduction; Sterol Regulatory Element Binding Protein 2; Triglycerides | 2016 |
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Ezetimibe; Fenofibrate; Humans; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Oxidation-Reduction; Phosphatidylethanolamine N-Methyltransferase; Triglycerides | 2017 |
Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation.
Topics: Animals; Anticholesteremic Agents; Azetidines; Biological Availability; Calorimetry, Differential Scanning; Capsules; Chemistry, Pharmaceutical; Cholesterol; Crystallography, X-Ray; Disease Models, Animal; Emulsions; Ezetimibe; Hydrogen-Ion Concentration; Hypercholesterolemia; Male; Microscopy, Electron, Scanning; Nanoparticles; Oils; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Solubility; Surface-Active Agents | 2008 |
A novel approach for prevention and dissolution of cholesterol gallstones.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Disease Models, Animal; Ezetimibe; Gallstones; Humans | 2008 |
Ezetimibe prevents cholesterol gallstone formation in mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; CD36 Antigens; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Duodenum; Ezetimibe; Female; Gallstones; Gene Expression; Humans; Intestinal Absorption; Liver; Male; Membrane Proteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL | 2008 |
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Line; Cell Movement; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Male; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies | 2009 |
Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish.
Topics: Age Factors; Aging; Animals; Animals, Genetically Modified; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Ezetimibe; Female; Green Fluorescent Proteins; Humans; Hypercholesterolemia; Larva; Lipid Metabolism; Lipoproteins; Luminescent Proteins; Macrophages; Male; Mice; Microscopy, Confocal; Oxidation-Reduction; Permeability; Phospholipases A2; Time Factors; Toll-Like Receptor 4; Zebrafish | 2009 |
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Topics: Acarbose; Animals; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholesterol; Dietary Fats; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Ezetimibe; Fatty Liver; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; PPAR alpha; Receptors, LDL; Sterol Regulatory Element Binding Protein 1; Triglycerides | 2009 |
High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Azetidines; Body Weight; Cholesterol; Disease Models, Animal; Ezetimibe; Magnetic Resonance Angiography; Mice; Mice, Inbred C57BL; Mice, Knockout; Reproducibility of Results; Time Factors | 2009 |
Ezetimibe - new anti-atherogenic properties?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; C-Reactive Protein; Cell Movement; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Macrophages; Monocytes; NF-kappa B; Rabbits; Simvastatin | 2009 |
Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model.
Topics: Animals; Anticholesteremic Agents; Azetidines; Coronary Restenosis; Disease Models, Animal; Drug Combinations; Drug Implants; Drug-Eluting Stents; Ezetimibe; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin; Swine; Treatment Outcome | 2010 |
A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Azetidines; Cholesterol, Dietary; Diet; Dietary Fats; Disease Models, Animal; Ezetimibe; Fatty Liver; Fibrosis; Gene Expression Profiling; Glucose; Humans; Liver; Male; Microarray Analysis; Molecular Sequence Data; Oxidative Stress; Rabbits | 2010 |
Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-48; Azetidines; Base Sequence; CD36 Antigens; Chylomicrons; Disease Models, Animal; DNA Primers; Ezetimibe; Fatty Acid Transport Proteins; Fatty Acid-Binding Proteins; Hypertriglyceridemia; Intestinal Absorption; Lipoproteins, VLDL; Lymph; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Postprandial Period; RNA, Messenger; Triglycerides; Triolein | 2010 |
Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cricetinae; Disease Models, Animal; Ezetimibe; Male; Prostatic Hyperplasia | 2010 |
Cholesterol intake modulates plasma triglyceride levels in glycosylphosphatidylinositol HDL-binding protein 1-deficient mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Dietary Fats; Disease Models, Animal; Ezetimibe; Liver; Mice; Receptors, Lipoprotein; Triglycerides | 2010 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles | 2011 |
Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Chylomicrons; Cricetinae; Diet, High-Fat; Disease Models, Animal; Ezetimibe; Glucose Tolerance Test; Male; Mesocricetus; Metabolic Syndrome; Treatment Outcome | 2012 |
Ezetimibe: A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia.
Topics: Animals; Azetidines; Bilirubin; Biomarkers; Crigler-Najjar Syndrome; Disease Models, Animal; Ezetimibe; Female; Genetic Therapy; Genetic Vectors; Glucuronosyltransferase; Humans; Liver; Liver Diseases; Male; Random Allocation; Rats; Rats, Gunn | 2012 |
Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
Topics: Animals; Anticholesteremic Agents; Azetidines; Disease Models, Animal; Ezetimibe; Fatty Acids; Fatty Liver; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Oryzias | 2012 |
Ezetimibe reduces intimal hyperplasia in rabbit jugular vein graft.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Azetidines; Calcium; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; Ezetimibe; Hyperplasia; Jugular Veins; Male; Rabbits; Transplantation, Autologous; Tunica Intima; Vascular Grafting; Vasodilation | 2012 |
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Body Weight; Cells, Cultured; Disease Models, Animal; Dyslipidemias; Ezetimibe; Fatty Liver; Hepatocytes; Insulin Resistance; Lipids; Metabolic Syndrome; Obesity; Rats; Rats, Zucker; Time Factors | 2007 |
Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Azetidines; Bile Acids and Salts; Body Weight; Cardiomegaly; Cholesterol; Coronary Artery Disease; Cyclic N-Oxides; Disease Models, Animal; Eating; Ezetimibe; Female; Fibrosis; Hypercholesterolemia; Intestinal Absorption; Life Expectancy; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Scavenger Receptors, Class B; Survival Rate; Triglycerides; Tropanes | 2008 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Azetidines; Cholesterol Esters; Cholesterol, Dietary; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Ezetimibe; Fatty Liver; Hepatomegaly; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Obesity; Time Factors; Triglycerides | 2008 |
Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Cholesterol, Dietary; Cortisone; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 7; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Gene Expression; Hypercholesterolemia; Hypophysectomy; Hypopituitarism; Injections, Subcutaneous; Intestinal Absorption; Lipoproteins; Liver; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Steroid Hydroxylases; Thyroxine; Treatment Outcome | 2008 |